Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04UWG
|
|||
| Former ID |
DIB008757
|
|||
| Drug Name |
Autologous T-cell therapy
|
|||
| Synonyms |
Anti-PSMA designer T cells, Roger Williams; Gene therapy (chimeric anti-PSMA antibody-TCR), Roger Williams; Autologous T-cell therapy (anti-PSMA-CD3, prostate cancer); Autologous T-cell therapy (anti-PSMA-CD3, prostate cancer), Roger Williams Medical Center; Retrovirus-based ex vivo gene therapy (anti-PSMA-CD3, prostate cancer), Roger Williams Medical Center
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 1 | [1] | |
| Company |
Roger Williams Medical Center
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunology. 2014 May 16;3(5):e16. | |||
| REF 2 | Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.